Business Context and Reporting Period
This Form 8-K is filed by PharmAthene, Inc. (not Altimmune, Inc.) on May 11, 2011. The report announces the financial and operating results for the quarter ended March 31, 2011. The company is incorporated in Delaware and maintains its principal executive offices in Annapolis, Maryland.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not disclose specific material changes versus the prior comparable period. It serves solely as a notification that the quarterly results have been issued via a press release.
Guidance, Outlook, and Risks
The text contains no management commentary, forward-looking guidance, risk factors, or discussion of unusual items. It explicitly states that the information in this report and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the May 11, 2011 press release).
- Confirm the company name is PharmAthene, Inc., as the input metadata incorrectly listed "Altimmune, Inc."
- Review the full press release for any operational updates or clinical trial milestones not detailed in this summary.